Metabolic Associated Fatty Liver Disease Increases the Risk of Systemic Complications and Mortality. A Meta-Analysis and Systematic Review of 12 620 736 Individuals

Endocrine Practice, Год журнала: 2022, Номер 28(7), С. 667 - 672

Опубликована: Март 30, 2022

Язык: Английский

---

Activation of Kupffer cells in NAFLD and NASH: mechanisms and therapeutic interventions

Frontiers in Cell and Developmental Biology, Год журнала: 2023, Номер 11

Опубликована: Май 16, 2023

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are emerging as the leading causes of worldwide. These conditions can lead to cirrhosis, cancer, failure, other related ailments. At present, transplantation remains sole treatment option for end-stage NASH, a rapidly growing socioeconomic burden. Kupffer cells (KCs) dominant population macrophages that reside in liver, playing crucial role innate immunity. Their primary function includes phagocytosing exogenous substances, presenting antigens, triggering immune responses. Moreover, they interact with during pathogenesis NAFLD, this crosstalk may either delay or exacerbate progression. Stimulation by endogenous signals triggers activation KCs, resulting expression various inflammatory factors chemokines, such NLRP3, TNF-α, IL-1B, IL-6, contributing cascade. In past 5 years, significant advances have been made understanding biological properties functions KCs including their interactions tissue molecules, underlying molecular mechanisms, signaling pathways, relevant therapeutic interventions. Having comprehensive these mechanisms characteristics enormous potential guiding future strategies prevention NAFLD.

Язык: Английский

---

NAFLD, MAFLD, and beyond: one or several acronyms for better comprehension and patient care

Internal and Emergency Medicine, Год журнала: 2023, Номер 18(4), С. 993 - 1006

Опубликована: Фев. 17, 2023

Abstract The term non-alcoholic fatty liver disease (NAFLD) has rapidly become the most common type of chronic disease. NAFLD points to excessive hepatic fat storage and no evidence secondary accumulation in patients with “no or little alcohol consumption”. Both etiology pathogenesis are largely unknown, a definitive therapy is lacking. Since very often closely associated metabolic dysfunctions, consensus process ongoing shift acronym MAFLD, i.e., metabolic-associated change terminology likely improve classification affected individuals, awareness, comprehension pathophysiological aspects involved, choice more personalized therapeutic approaches while avoiding intrinsic stigmatization due “non-alcoholic”. Even recently, other sub-classifications have been proposed concentrate heterogeneous causes under one umbrella. While awaiting additional validation studies this field, we discuss main reasons underlying important paradigm.

Язык: Английский

---

Epidemiology and Clinical Outcomes of Metabolic (Dysfunction)-associated Fatty Liver Disease

Journal of Clinical and Translational Hepatology, Год журнала: 2021, Номер 000(000), С. 000 - 000

Опубликована: Авг. 30, 2021

Metabolic (dysfunction)-associated fatty liver disease (MAFLD) is currently the most common chronic and affects at least a quarter of global adult population. It has rapidly become one leading causes hepatocellular carcinoma cirrhosis in Western countries. In this review, we discuss nomenclature definition MAFLD as well its prevalence incidence different geographical regions. Although cardiovascular remains cause death patients, proportion patients dying from hepatic complications increases sharply progresses to advanced fibrosis cirrhosis. addition, with are increased risk various extrahepatic cancers. causal relationship between cancers not been established, clinicians should recognize association consider cancer screening (e.g., for colorectal cancer) appropriate.

Язык: Английский

---

The Egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease

Saudi Journal of Gastroenterology, Год журнала: 2022, Номер 28(1), С. 3 - 20

Опубликована: Янв. 1, 2022

The landscape of chronic liver disease in Egypt has drastically changed over the past few decades. prevalence metabolic-associated fatty (MAFLD) risen to alarming levels. Despite magnitude problem, no regional guidelines have been developed tackle this disease. This document provides clinical practice key Egyptian opinion leaders on MAFLD screening, diagnosis, and management, covers various aspects management MAFLD. considers our local situations burden for healthcare sector is proposed daily practical use. Particular reference special groups was done whenever necessary.

Язык: Английский

---

Metabolic-associated fatty liver disease: New nomenclature and approach with hot debate

World Journal of Hepatology, Год журнала: 2023, Номер 15(2), С. 123 - 128

Опубликована: Фев. 24, 2023

An international panel recently proposed an update to the terminology and diagnostic criteria for fatty liver disease. The experts a change in nomenclature from non-alcoholic disease (NAFLD) metabolic (dysfunction)-associated (MAFLD). This single-letter change, we believe, heralds dawn of new era clinical practice basic research as well. with easily applicable approach has stimulated enthusiasm researchers worldwide, resulting large number publications over past two years. Several recent studies have provided tremendous evidence superiority MAFLD NAFLD criteria. Many different geographic areas world including United States, Europe, Asia on patients proved that utility was higher than aspects diseases. Consequently, many societies, physician nurse groups, health stakeholders, representatives regulatory sciences, others endorsed nomenclature. Here highlight endorsement name by societies groups outcome addition short discussion debate some experts.

Язык: Английский

---

Joint position statement from the Middle East and North Africa and sub-Saharan Africa on continuing to endorse the MAFLD definition

Journal of Hepatology, Год журнала: 2024, Номер 80(5), С. e194 - e197

Опубликована: Фев. 10, 2024

A multisociety Delphi consensus statement on new fatty liver disease nomenclatureJournal of HepatologyVol. 79Issue 6PreviewThe principal limitations the terms NAFLD and NASH are reliance exclusionary confounder use potentially stigmatising language. This study set out to determine if content experts patient advocates were in favour a change nomenclature and/or definition. modified process was led by three large pan-national associations. The defined priori as supermajority (67%) vote. An independent committee external made final recommendation acronym its diagnostic criteria. Full-Text PDF Open Access In tremendous conceptual advance, Eslam et al.1Eslam M. Newsome P.N. Sarin S.K. al.A definition for metabolic dysfunction-associated disease: an international expert statement.J Hepatol. 2020; 73: 202-209Abstract Full Text PubMed Scopus (2259) Google Scholar, 2Eslam Sanyal A.J. George J. al.MAFLD: consensus-driven proposed associated disease.Gastroenterology. 158: 1999-2014. e1Abstract (1854) 3Eslam Alkhouri N. Vajro P. al.Defining paediatric (dysfunction)-associated statement.Lancet Gastroenterol 2021; 6: 864-873Abstract (126) Scholar put forth two landmark articles that changed narrative with dysfunction, including correction from non-alcoholic (NAFLD) (MAFLD) more apt term. They also introduced simple appropriate "positive" criteria diagnosing disease, alcohol intake or other diseases. These apply both adults children is continuum across lifespan. We among societies stakeholders endorsed this proposal multitude reasons,4Shiha G. Alswat K. Al Khatry al.Nomenclature metabolic-associated Middle East north Africa.Lancet 57-64Abstract (111) 5Spearman C.W. Desalegn H. Ocama al.The sub-Saharan Africa position redefinition MAFLD.J 74: 1256-1258Abstract (37) 6Méndez-Sánchez Bugianesi E. Gish R.G. al.Global multi-stakeholder endorsement MAFLD definition.Lancet 2022; 7: 388-390Abstract (147) a) value evidence: wealth data have provided unequivocal evidence superior utility compared traditional various outcomes.7Alharthi Gastaldelli A. Cua I.H. Ghazinian Metabolic year review.Curr Opin Gastroenterol. 38: 251-260Crossref (38) b) simplicity practicality these c) Nomenclature devoid any stigma appropriately reflects pathophysiology makes it easier communicate patients, general practitioners, nurses, non-hepatology specialists policy makers.8Shiha Korenjak Eskridge W. al.Redefining perspective.Lancet 73-79Abstract (131) 9Clayton Fabrellas Luo al.From MAFLD: nurse allied health perspective.Liver Int. 41: 683-691Crossref (34) 10Farahat T.M. Ungan Vilaseca paradigm shift global primary care viewpoint.Liver 42: 1259-1267Crossref (14) 11Eslam Ahmed Després J.-P. al.Incorporating multidisciplinary novel clinical trial designs patients diseases.Lancet 743-753Abstract (56) Recently after lengthy complex raised questions than resolved, attempt develop another disease. group under umbrella using term steatotic disease" (MASLD) adopted MAFLD.12Rinella M.E. Lazarus J.V. Ratziu V. multi-society nomenclature.Ann 2023; 101133PubMed As regional leaders, whose utmost priority our we spent several months analysing views stance it. Consequently, African Association Gastroenterology (AMAGE), we, undersigned, comprising over 100 signatories representing multiple key opinion leaders 31 countries, decided continue name overarching diseases dysregulation official terminology region. decision based on: 1) Emerging suggesting accurately underlying pathogenesis better at identifying those high risk outcomes MASLD At minimum, did not lead significant improvements can justify confusion could be caused change.13Chen L. Tao X. Zeng Mi Y. Xu Clinical histological features different nomenclatures NAFLD, MAFLD, MetALD.J Scholar,14Zhao Q. Deng Comparison mortality individuals Abstract (7) Additionally, numerous studies demonstrated lack granularity specificity15Tanaka Mori Takahashi S. al.Metabolic dysfunction–associated predicts onset chronic kidney nonalcoholic disease.Nephrol Dial Transplant. 700-711Crossref (20) Scholar,16Anirvan Khatua C.R. Panigrahi M.K. Singh S.P. Definition dysfunction: shifting goalposts.J Clin Exp Scholar. Therefore, only one maintains right balance between sensitivity specificity. finding expected implications cost-effective analysis. 2) argument "fatty" stigmatising. However, statements refuted claim. point has been illustrated patients' spokespeople, who highlighted "in some cultures being fat regarded sign good health".17Shiha Casanovas T. al.MAFLD 2022: ELPA/ALPA/EASO-ECPO joint stigma.J 77: 1717-1719Abstract (12) recent showed perception varies significantly providers, geographic locations, sub-specialties. Only 8% perceived 38% doctors.18Younossi Z.M. AlQahtani S.A. survey physicians disease.J Another necessarily all cultures.19Méndez-Sánchez Pal S.C. Fassio Díaz-Ferrer Prado-Robles J.A. stigma—a single-center Mexican survey.Hepatol 17: 507-508Crossref (6) "steatotic" same translation languages spoken believe findings collectively weaken changing "steatotic". sufficient basis avoid abrupt changes Studies shown transition positive increasing awareness healthcare providers. It increases attention conferences countries systems.20Fouad Gomaa Semida Ghany W.A. Attia D. Change specialists.J 1254-1256Abstract (51) Scholar,21Fouad Abdel Salam AbdAllah expands information flow.Hepatol Res. 52: 488-489Crossref (2) conclusion, considering North Africa, well Sub-Saharan endorse instead opted existing before. Asian Pacific Study Liver (APASL) taken decision. Further confirm validity needed. No funding obtained required study. All authors nothing disclose relevant work. Please refer accompanying ICMJE disclosure forms further details. shared conceptualisation designed idea. Yasser Fouad wrote initial draft. revised manuscript approved version. contributing list: Sherief M Abd-elsalam Tropical Medicine Infectious Diseases Department, Faculty Medicine, Tanta University, Tanta, Egypt. Mohamed Department Gastroenterology, Hepatology, Medical Research Division, National Center, Nermeen Abdeen Alexandria Alexandria. Shereen Abdelaleem Endemic Cairo Cairo, Abdelghani Hepatology Minia Minia, Wafaa Abdelhamid Haitham Hamid Nadia Abdelaaty Ain Shams Mostafa Abdellhalim Ministry Health population, Abdelmohsen Assiut Assiut, Doaa Abdeltawab Mosaab Abdulkarim Tripoli medical university, Libya. Bounena Abidine Centre Hospitalier de Nouakchott, Mauritania. Aboalela YousryAboamer Mahala Teaching Hospital, Sayed Mohammed Amer Internal Al-Azhar Kafya Akrouf Al-Amiri Kuwait City, Kuwait. Hameed Jameel university Kerbala, Iraq. Munira Tarrah Abeer Al-Gharabally Nourhan Alaa Ataa Pezhman Alavinejad School Alimentary Tract Imam Khomeini Ahvaz Jundishapur University Sciences, Khuzestan, Iran. Moussa Ali Mahamat Chad. Alice Guingané Département d'Hépato-gastroentérologie, Universitaire Yalgado Ouédraogo, Ouagadougou, Burkina Faso. Taha Alkarboly Kurdistan Center Assulaymaniah, Kurdistan, Nawal Alkhalidi & Environment, Baghdad, Abdullah Alyouzbaki College Mosul, Nazugum Ashimova Astana Astana, Kazakhstan. Badi Hamad corporation, Qatar. Ibrahim Halil Bahcecioglu Firat Turkey. Shamardan Bazeed South Valley Qena, Asad Dajani ADSC, Medcare Hospital Saudi German Sharjah, Khan, PO Box 6328, United Arab Emirates. Mahmoud Desoky Division Sultan bin Abdulalaziz city, Arabia. Ibrahima Diallo Hepatogastroenterology, Hôpital Principal Dakar, Senegal. Elbadri Corporation, Amr Elsayed tropical medicine department, Aisha Elsharkawy Elwazzan Alexandria, Eman Fares Fayoum Manar Farhat Yasmine Gaber Manik Gemilyan Yerevan State Armenia. Yahya Ghanem Sanaa college, Yemen. Fayoum, Gueye Président Saafara Hépatites, Sénégal. Azaa Hafez Nursing, Gagik Hakobyan Adel Hasan Suez Canal Suez, Fuad Royale Hayat Alshymaa Hassnine Hassanin Bilal Hotayt Khoury Hamra, Beirut, Lebanon. Alkassoum Salifou Abdou Moumouni Niamey, Niger. Enas Kamal Qalandar Kasnazan Higher Council Fir Specialities, KHCMS, Rofida Khalifa Ashkhen Keryan Nikomed center, Khan King Abdulla Mecca, Saro Khemichyan Gastrointestinal Diseases, Keck USC, Elmira Kuantay S.D. Asfendiyarov Kazakh Liver, Almaty, Dlovan Khoushnow DK radiology clinic, Erbil Governorate, Reem Mahdy Assuit Amna Saltanat Madenova Gayane Matsakyan Nahed Makhlouf Assuit, Mai Mehrez Armed Forces Souraia Mezhoud corporation HMC, Eileen Micah Komfo Anokye Kumasi, Ghana. Safaa Abdelhalim Menna centre, Shaymaa Nafady Beni-Suef Beni Suef, Aren Nersisyan Alexander Nersesov Kalys Nogoibaeva Kyrgyz Academi, Kyrgyzstan. Necati ORMECİ İstanbul Technology Istanbul, Türkiye. Marian Muse Osman Somalia Institute Health, Somalia. Venera Rakhmetova Abdulfattah Rajab department Central Aigul Raissova Ebada Said Benha Benha, Asmaa Salama Ruzanna Safaryan Violeta Sargsyan Nady Semeda Nara Stepanyan Isaac Thom Shawa Malawi Blantyre, Malawi. Aya Shazly health, Taharboucht CHU Douera, Blida, Algiers, Algeria. Tumi Liya, Mariam Zaghloul Kafrelsheikh University,Egypt. Samy Zaky Hepatogastroenterology following supplementary article: Download .pdf (.95 MB) Help pdf files Multimedia component 1

Язык: Английский

---

Redefinition of fatty liver disease from NAFLD to MAFLD raised disease awareness: Mexican experience

Journal of Hepatology, Год журнала: 2021, Номер 75(1), С. 221 - 222

Опубликована: Апрель 21, 2021

Язык: Английский

---

NAFLD: Challenges and opportunities to address the public health problem in Latin America

Annals of Hepatology, Год журнала: 2021, Номер 24, С. 100359 - 100359

Опубликована: Май 15, 2021

Non-alcoholic fatty liver disease (NAFLD) is reaching epidemic proportions worldwide. Collectively, Latin American countries have some of the highest obesity rates in world and fastest-growing prevalence type 2 diabetes mellitus (T2DM). Since T2DM are intrinsically linked with NAFLD, epidemiological projections worrisome. In addition to this adverse setting, region America faces unique challenges obstacles addressing growing burden NAFLD. article, on occasion International NASH Day June 10, 2021, we describe main opportunities improve care people living NAFLD America. Among major be tackled are: lack awareness, limited educational for healthcare personnel general public, health system fragmentation, effective strategies prevention treatment common comorbidities, namely T2DM. Wide dissemination current concepts extensive collaboration between scientific societies, governments, non-governmental organizations, pharmaceutical industry, other stakeholders urgently needed advance public policies agenda that allows us address a whole society approach.

Язык: Английский

---

The Spectrum and Impact of Metabolic Dysfunction in MAFLD: A Longitudinal Cohort Analysis of 32,683 Overweight and Obese Individuals

Clinical Gastroenterology and Hepatology, Год журнала: 2022, Номер 21(10), С. 2560 - 2569.e15

Опубликована: Окт. 3, 2022

Язык: Английский

---